Table 1 (continued)
lncRNA
Disease
Oncogenic/tumoursuppressive effects
Potential
clinical
applications
References
MIAT
Chronic lymphocytic
leukaemia (CLL)
• Evasion of cell
death
• Prognostic
biomarker
[47]
Breast cancer
• Proliferation
• Metastasis
• Prognostic
biomarker
[127]
Lung cancer
• Proliferation
• Metastasis
• Prognostic
biomarker
• Therapeutic
target
[48, 128,
129]
TUG1
Glioblastoma
• Proliferation
• CSC maintenance
• Therapeutic
target
[68, 130]
RCC
• Proliferation
• Evasion of cell
death
• Metastasis
• Prognostic
biomarker
• Therapeutic
target
[42, 131]
Osteosarcoma
• Proliferation
• Evasion of cell
death
• Metastasis
• Therapeutic
target
[44, 132,
133]
ANRIL
Gastric cancer
• Proliferation
• Multiple drug
resistance
• Prognostic
biomarker
• Therapeutic
target
[134, 135]
Osteosarcoma
• Proliferation
• Metastasis
• Prognostic
biomarker
• Therapeutic
target
[136, 137]
Downregulated in cancer
lincRNAp21
CRC
• Growth suppression
• Self-renewal suppression
• Radiosensitivity
• Prognostic
biomarker
• Therapeutic
target
[138–140]
Prostate cancer (PCa)
• Proliferation suppression
• Apoptosis
• Therapeutic
target
[141, 142]
TB53TG1 CRC
• Proliferation suppression
• Metastasis
inhibition
• Prognostic
biomarker
[50]
MEG3
Pancreatic cancer
• Growth inhibition
• Apoptosis
• Metastasis inhibition
• Gemcitabine
sensitivity
• Prognostic
biomarker
[143, 144]
Lung cancer
• Proliferation suppression
• Apoptosis
• Chemosensitivity
• Therapeutic
target
[145–148]
Altered Long Non-coding RNA Expression in Cancer: Potential Biomarkers. . .
411